ES2656438T3 - Composición para el tratamiento de enfermedades degenerativas de las articulaciones - Google Patents
Composición para el tratamiento de enfermedades degenerativas de las articulaciones Download PDFInfo
- Publication number
- ES2656438T3 ES2656438T3 ES10725744.6T ES10725744T ES2656438T3 ES 2656438 T3 ES2656438 T3 ES 2656438T3 ES 10725744 T ES10725744 T ES 10725744T ES 2656438 T3 ES2656438 T3 ES 2656438T3
- Authority
- ES
- Spain
- Prior art keywords
- powder
- collagen hydrolyzate
- approx
- composition
- collagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract description 3
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 102000008186 Collagen Human genes 0.000 abstract description 13
- 108010035532 Collagen Proteins 0.000 abstract description 13
- 229920001436 collagen Polymers 0.000 abstract description 13
- 239000000843 powder Substances 0.000 abstract description 11
- 241000220317 Rosa Species 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 description 8
- 102000016611 Proteoglycans Human genes 0.000 description 4
- 108010067787 Proteoglycans Proteins 0.000 description 4
- 102000016284 Aggrecans Human genes 0.000 description 2
- 108010067219 Aggrecans Proteins 0.000 description 2
- 230000036570 collagen biosynthesis Effects 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición que comprende hidrolizado de colágeno y polvo y/o extracto de escaramujo, en donde la relación ponderal de hidrolizado de colágeno a polvo y/o extracto de escaramujo, en cada caso referido a la masa seca, se encuentra en el intervalo de aprox. 10:1 a aprox. 20:1.
Description
5
10
15
20
25
30
menos siete determinaciones independientes. La biosíntesis de colágeno se aumenta en aprox. 25% mediante la adición de hidrolizado de colágeno, mediante la adición de polvo de escaramujo únicamente en aprox. 5%. En el caso de la adición simultánea de hidrolizado de colágeno y polvo de escaramujo (en una relación ponderal de 10:1) se observa, sin embargo, un aumento de aprox. 50%.
En el caso de los valores representados en la Figura 8 para la biosíntesis de proteoglicanos se muestra todavía más claramente la presencia de un efecto sinérgico. La adición de polvo de escaramujo solo (tanda M) conduce a una biosíntesis de proteoglicanos algo menor que en el caso del control (tanda K), mientras que mediante la combinación de polvo de escaramujo con hidrolizado de colágeno (tanda N) se alcanza un aumento aproximadamente dos veces y medio tan alto que mediante el hidrolizado de colágeno solo (tanda L).
La expresión de ARN de colágeno (Figura 9) y ARN de agrecano (Figura 10) muestra una imagen similar. El aumento de la expresión con respecto al control es en el caso de la tanda N aproximadamente tres veces tan alto (ARN de colágeno) o bien aproximadamente dos veces tan alto (ARN de agrecano) como en el caso de la tanda L.
Con el fin de determinar la influencia de la cantidad del polvo de escaramujo empleado se llevó a cabo una serie de ensayos con las siguientes tandas de cultivos celulares:
Tanda O: control (sin hidrolizado de colágeno o polvo de escaramujo)
Tanda P: 0,5 mg/ml de hidrolizado de colágeno
Tanda Q: 0,5 mg/ml de hidrolizado de colágeno y 0,005 mg/ml de polvo de escaramujo
Tanda R: 0,5 mg/ml de hidrolizado de colágeno y 0,05 mg/ml de polvo de escaramujo
Tanda S: 0,5 mg/ml de hidrolizado de colágeno y 0,5 mg/ml de polvo de escaramujo.
La Figura 11 muestra los resultados en relación con la biosíntesis de colágeno y la Figura 12 en relación con la biosíntesis de proteoglicanos. En el caso de la tanda Q (relación ponderal de hidrolizado de colágeno a polvo de escaramujo de 100:1) se manifiesta un efecto sólo ligeramente mayor o bien menor que en el caso de la tanda P (sólo hidrolizado de colágeno), es decir, un aumento de la biosíntesis en el intervalo de aprox. 20%. En el caso de la tanda R (relación ponderal de 10:1) se observa de nuevo en cada caso un aumento significativo de la biosíntesis en aprox. 50%, correspondiente a la tanda N anterior. Un aumento ulterior de la proporción de polvo de escaramujo a una relación ponderal de 1:1 (tanda S) conduce tanto en la biosíntesis del colágeno como en la biosíntesis de proteoglicanos a un aumento algo menor que en el caso de la tanda R.
Los resultados precedentemente descritos confirman que mediante la adición de extracto de escaramujo o polvo de escaramujo se puede potenciar de manera significativa el efecto estimulante de hidrolizado de colágeno sobre la biosíntesis de los componentes principales de la matriz extracelular del tejido cartilaginoso. Una composición que contiene hidrolizado de colágeno y polvo y/o extracto de escaramujo en la relación ponderal de aprox. 2:1 hasta aprox. 100:1 puede emplearse entonces como un medicamento o suplemento dietético eficaz para el tratamiento o la prevención de enfermedades degenerativas de las articulaciones.
8
Claims (1)
-
imagen1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102009030351 | 2009-06-22 | ||
| DE102009030351A DE102009030351A1 (de) | 2009-06-22 | 2009-06-22 | Zusammensetzung zur Behandlung von degenerativen Gelenkerkrankungen |
| PCT/EP2010/058674 WO2010149596A1 (de) | 2009-06-22 | 2010-06-18 | Zusammensetzung zur behandlung von degenerativen gelenkerkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2656438T3 true ES2656438T3 (es) | 2018-02-27 |
Family
ID=42731926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10725744.6T Active ES2656438T3 (es) | 2009-06-22 | 2010-06-18 | Composición para el tratamiento de enfermedades degenerativas de las articulaciones |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8778422B2 (es) |
| EP (1) | EP2445510B1 (es) |
| CN (1) | CN102573867B (es) |
| AU (1) | AU2010264800B2 (es) |
| DE (1) | DE102009030351A1 (es) |
| ES (1) | ES2656438T3 (es) |
| MX (1) | MX2012000029A (es) |
| PL (1) | PL2445510T3 (es) |
| SG (1) | SG176965A1 (es) |
| WO (1) | WO2010149596A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK177605B1 (en) * | 2010-03-16 | 2013-11-18 | Hyben Vital Licens Aps | Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis |
| PL2785420T3 (pl) * | 2011-11-29 | 2018-08-31 | Gelita Ag | Kosmetyczne zastosowanie hydrolizatu kolagenu |
| DE102012110612A1 (de) * | 2012-11-06 | 2014-05-08 | Gelita Ag | Kollagenhydrolysat und dessen Verwendung |
| DE102013104897A1 (de) * | 2013-05-13 | 2014-11-13 | Gelita Ag | Wirkstoff zur Behandlung von Sarkopenie |
| US10226513B2 (en) | 2015-01-09 | 2019-03-12 | Mark Terrell Smith | Method and composition to prevent or improve symptoms of musculoskeletal distress degeneration |
| EP3053458B1 (en) * | 2015-01-28 | 2019-10-30 | Paninkret Chemisch-Pharmazeutisches Werk GmbH | Spray-Dried Composition Comprising an Acerola Fruit Extract, Hydrolyzed Collagen Type II and Chondroitin Sulfate |
| DE202015101782U1 (de) | 2015-04-13 | 2015-06-01 | Gelita Ag | Synergistische Kollagenhydrolysat-Zusammensetzung |
| CA2950096C (en) * | 2016-11-28 | 2022-04-12 | Corporation Genacol Canada Inc. | Use of low molecular weight collagen hydrolysate for preventing and/or reducing joint pain, lateral meniscal protusion and/or improving cartilage abrasion grade |
| US11998654B2 (en) | 2018-07-12 | 2024-06-04 | Bard Shannon Limited | Securing implants and medical devices |
| DE102019207859A1 (de) * | 2018-12-21 | 2020-06-25 | Gelita Ag | Synthetische und rekombinant hergestellte Kollagenpeptide mit biologischer Wirksamkeit |
| CN109395055A (zh) * | 2019-01-07 | 2019-03-01 | 琪庆生物医药(上海)有限公司 | 一种具有修复关节软组织损伤作用的组合物及其制备方法 |
| JP6777794B1 (ja) * | 2019-07-04 | 2020-10-28 | 株式会社ファンケル | コラーゲン産生促進用組成物 |
| DE102020210725A1 (de) | 2019-10-31 | 2021-05-06 | Gelita Ag | Ernährungsphysiologisch optimiertes Kollagenpeptid |
| US12520859B2 (en) | 2020-01-13 | 2026-01-13 | Cargill, Incorporated | Turkey collagen hydrolysates and methods of making |
| CN115300603A (zh) * | 2022-07-25 | 2022-11-08 | 穆棱市晟宇生物科技有限公司 | 一种用于风湿免疫性疾病的组合物、制备方法及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1302880C (en) | 1986-07-25 | 1992-06-09 | Peter Koepff | Agents for the treatment of arthroses |
| US6024960A (en) | 1998-04-17 | 2000-02-15 | Otto Torbjorn Hansen And Marianne Hansen | Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis |
| JP2001238639A (ja) * | 2000-03-02 | 2001-09-04 | Medical Salon Brand:Kk | ビタミンｃ及びクロムからなる栄養補助食品 |
| JP2004113141A (ja) * | 2002-09-26 | 2004-04-15 | Daawinzu:Kk | Ｍｓｍ含有の健康食品 |
| US7348034B2 (en) * | 2005-03-07 | 2008-03-25 | Access Business Group International Llc | Plant based formulations for improving skin moisture, texture, and appearance |
| WO2007024901A1 (en) * | 2005-08-23 | 2007-03-01 | Access Business Group International Llc | Cytokine modulators and related methods of use |
| US8017162B2 (en) * | 2005-10-26 | 2011-09-13 | Oryza Oil & Fat Chemical Co., Ltd. | Anti-inflammatory agent |
| ATE524483T1 (de) * | 2006-07-03 | 2011-09-15 | Hyben Vital Licens Aps | Verfahren zur herstellung eines glykosids eines mono- oder diacylglyzerinprodukts aus einem pflanzlichen material |
| WO2008006582A1 (en) * | 2006-07-14 | 2008-01-17 | Dsm Ip Assets B.V. | Compositions comprising magnolol or honokiol and other active agents for the treatment of inflammatory diseases |
| US20100055218A1 (en) * | 2006-07-14 | 2010-03-04 | Daniel Raederstorff | Novel compositions |
| DK2224939T3 (da) * | 2007-12-21 | 2015-06-22 | Finzelberg Gmbh & Co Kg | Præparater med hybenekstrakt, og fremgangsmåde til fremstilling af hybenekstrakt |
-
2009
- 2009-06-22 DE DE102009030351A patent/DE102009030351A1/de not_active Withdrawn
-
2010
- 2010-06-18 AU AU2010264800A patent/AU2010264800B2/en active Active
- 2010-06-18 ES ES10725744.6T patent/ES2656438T3/es active Active
- 2010-06-18 WO PCT/EP2010/058674 patent/WO2010149596A1/de not_active Ceased
- 2010-06-18 CN CN201080027874.6A patent/CN102573867B/zh active Active
- 2010-06-18 MX MX2012000029A patent/MX2012000029A/es active IP Right Grant
- 2010-06-18 EP EP10725744.6A patent/EP2445510B1/de active Active
- 2010-06-18 PL PL10725744T patent/PL2445510T3/pl unknown
- 2010-06-18 SG SG2011095445A patent/SG176965A1/en unknown
-
2011
- 2011-12-20 US US13/331,401 patent/US8778422B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010149596A1 (de) | 2010-12-29 |
| AU2010264800B2 (en) | 2015-08-27 |
| DE102009030351A1 (de) | 2010-12-23 |
| AU2010264800A1 (en) | 2012-02-16 |
| EP2445510A1 (de) | 2012-05-02 |
| US8778422B2 (en) | 2014-07-15 |
| MX2012000029A (es) | 2012-01-30 |
| PL2445510T3 (pl) | 2018-06-29 |
| EP2445510B1 (de) | 2017-12-27 |
| CN102573867A (zh) | 2012-07-11 |
| BRPI1015228A2 (pt) | 2016-05-03 |
| US20120128737A1 (en) | 2012-05-24 |
| SG176965A1 (en) | 2012-01-30 |
| CN102573867B (zh) | 2014-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2656438T3 (es) | Composición para el tratamiento de enfermedades degenerativas de las articulaciones | |
| Silva et al. | Effectiveness of plant-derived proanthocyanidins on demineralization on enamel and dentin under artificial cariogenic challenge | |
| ES2587928T3 (es) | Hidrolizado de colágeno y su uso | |
| NZ594022A (en) | Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof | |
| UA103221C2 (uk) | Стабільний склад рекомбінантного альбуміну людини-гранулоцитарного колонієстимулюючого фактора людини | |
| BR122020001787A8 (pt) | Conjugado de anticorpo-agente ativo, seus métodos de preparação, sua composição e seu uso | |
| WO2009142770A3 (en) | Compositions and methods for generating musculoskeletal tissue | |
| MX2009004439A (es) | Composicion de ibuprofeno. | |
| MY160412A (en) | Oral compositions containing extracts of zingiber officinale and related methods | |
| SG171649A1 (en) | Dpp iv inhibitor formulations | |
| PH12012501522A1 (en) | Oral care compositions | |
| UA106636C2 (uk) | Морфолінотіазоли як позитивні алостеричні модулятори альфа 7 | |
| TR201911258T4 (tr) | 3D in vitro çift fazlı kıkırdak-kemik yapısı. | |
| PH12012501620A1 (en) | Oral care compositions | |
| BR112013012697A2 (pt) | "método para diminuir expressão, produção ou secreção de um fator angiogênico ou fator hipertrófico ou ambos por células-tronco mesenquimais, métodos para diminuir um efeito inibidor, um efeito deletério, e um efeito de apoptose de células-tronco mesenquimais, método para aumentar um efeito estimulador de células-tronco mesenquimais, composição, e, método para preparar cartilagem em um indivíduo diagnosticado com cartilagem doente ou danificada." | |
| SG10201908916UA (en) | Stable MIA/CD-RAP formulations | |
| PH12013502215A1 (en) | Beautiful-skin-promoting agent and use thereof | |
| MX2012002785A (es) | Derivado de indenona y composicion farmaceutica que comprende el mismo. | |
| MX357554B (es) | Concentrado o extracto de brote de aloe vera que tiene efectos superiores de promoción de célula de la piel, antioxidantes y anti-alergia. | |
| PT2459153E (pt) | Composição farmacêutica ou cosmética ou dietética tendo o efeito de favorecer a pigmentação capilar | |
| AR079375A1 (es) | Soluciones de rehidratacion oral que comprenden dextrosa. metodo de preparacion. | |
| German et al. | Exploring the impact of catechins on bone metabolism: a comprehensive review of current research and future directions | |
| JO2229B1 (en) | Stem cells are programmable, distinctly regenerative, of single-core cell origin, production, and use | |
| MX2010004556A (es) | Formulacion farmaceutica de acido clavulanico. | |
| AR118208A1 (es) | Composiciones para evitar, mejorar o tratar enfermedades o síntomas relacionados con los cartílagos, que comprenden hapln1 |